PUNE, India, April 29, 2016 /PRNewswire/ --
ReportsnReports.com adds "Pulmonary Arterial Hypertension - Pipeline Review, H1 2016" market research report that provides an overview of the PAH therapeutic pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.
Companies discussed in this Pulmonary Arterial Hypertension Pipeline Review, H1 2016 report include APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca, S.A., Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celsion Corporation, Complexa, Inc., Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Insmed Incorporated, INVENT Pharmaceuticals, Inc., Johnson & Johnson, Kowa Company, Ltd., Mallinckrodt Plc, Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Morphogen-IX Limited, Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis AG, Peloton Therapeutics, Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo, Inc., Pulmokine, Inc., Reata Pharmaceuticals, Inc., Respira Therapeutics, Inc., Selten Pharma, Inc, Silence Therapeutics Plc, SteadyMed Therapeutics, Inc., Suda Ltd and Toray Industries, Inc.
Complete report on H1 2016 pipeline review of Pulmonary Arterial Hypertension with 62 market data tables and 16 figures, spread across 202 pages is available at http://www.reportsnreports.com/reports/538046-pulmonary-arterial-hypertension-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Drug profiles discussed in this research report includes Antibody for Pulmonary Arterial Hypertension, Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension, APT-602, bardoxolone methyl, beraprost sodium ER, beraprost sodium SR, BIA-51058, BMP-9, CT-2009, CXA-10, Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension, fasudil, imatinib mesylate, INS-1009, INV-240, JNJ-26993135, lisuride, MFC-001, MFC-002, nitric oxide, Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension, Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension, PB-1046, PB-1120, pitavastatin NP, PK-10453, PK-10571, PLX-PAD, PT-2977, QCC-374, R-190, ralinepag, RT-234, selexipag, selonsertib, sirolimus albumin-bound, Small Molecule for Pulmonary Arterial Hypertension, Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction, Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension, Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension, Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension, Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension, SPI-054, SPI-183, SUD-004, Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction, Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension, tacrolimus, tadalafil, tiprelestat, tocilizumab, TR-422, treprostinil, treprostinil diolamine, TXA-127, ubenimex and udenafil.
Order a copy of this PAH pipeline report for H1 2016 @ http://www.reportsnreports.com/Purchase.aspx?name=538046 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension and reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Another newly published market research report titled on Portal Hypertension - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Portal Hypertension Pipeline market research report of 73 pages is available at http://www.reportsnreports.com/reports/538071-portal-hypertension-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. + 1 888 391 5441 [email protected]
SOURCE ReportsnReports
Advertisement
ReportsnReports.com adds "Pulmonary Arterial Hypertension - Pipeline Review, H1 2016" market research report that provides an overview of the PAH therapeutic pipeline, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.
Advertisement
Companies discussed in this Pulmonary Arterial Hypertension Pipeline Review, H1 2016 report include APT Therapeutics, Inc., Arena Pharmaceuticals, Inc., Asahi Kasei Pharma Corp., Ascendis Pharma A/S, Bial - Portela & Ca, S.A., Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celsion Corporation, Complexa, Inc., Corridor Pharmaceuticals Inc., Cytokinetics, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Insmed Incorporated, INVENT Pharmaceuticals, Inc., Johnson & Johnson, Kowa Company, Ltd., Mallinckrodt Plc, Mezzion Pharma Co. Ltd., miRagen Therapeutics, Inc., Morphogen-IX Limited, Nippon Kayaku Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis AG, Peloton Therapeutics, Inc., PharmaIN Corporation, PhaseBio Pharmaceuticals, Inc., Pluristem Therapeutics Inc., Proteo, Inc., Pulmokine, Inc., Reata Pharmaceuticals, Inc., Respira Therapeutics, Inc., Selten Pharma, Inc, Silence Therapeutics Plc, SteadyMed Therapeutics, Inc., Suda Ltd and Toray Industries, Inc.
Complete report on H1 2016 pipeline review of Pulmonary Arterial Hypertension with 62 market data tables and 16 figures, spread across 202 pages is available at http://www.reportsnreports.com/reports/538046-pulmonary-arterial-hypertension-pipeline-review-h1-2016.html .
The report also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Drug profiles discussed in this research report includes Antibody for Pulmonary Arterial Hypertension, Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension, APT-602, bardoxolone methyl, beraprost sodium ER, beraprost sodium SR, BIA-51058, BMP-9, CT-2009, CXA-10, Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension, fasudil, imatinib mesylate, INS-1009, INV-240, JNJ-26993135, lisuride, MFC-001, MFC-002, nitric oxide, Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension, Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension, PB-1046, PB-1120, pitavastatin NP, PK-10453, PK-10571, PLX-PAD, PT-2977, QCC-374, R-190, ralinepag, RT-234, selexipag, selonsertib, sirolimus albumin-bound, Small Molecule for Pulmonary Arterial Hypertension, Small Molecule to Inhibit Arginase for Vascular Dysfunction, PAH and Erectile Dysfunction, Small Molecule to Inhibit Myosin for COPD, Asthma And Pulmonary Arterial Hypertension, Small Molecule to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension, Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension, Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension, SPI-054, SPI-183, SUD-004, Synthetic Peptide for Immunology, Cardiovascular Diseases, Respiratory Diseases and Female Sexual Dysfunction, Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension, tacrolimus, tadalafil, tiprelestat, tocilizumab, TR-422, treprostinil, treprostinil diolamine, TXA-127, ubenimex and udenafil.
Order a copy of this PAH pipeline report for H1 2016 @ http://www.reportsnreports.com/Purchase.aspx?name=538046 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension and reviews pipeline therapeutics for Pulmonary Arterial Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Pulmonary Arterial Hypertension therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Pulmonary Arterial Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Another newly published market research report titled on Portal Hypertension - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Portal Hypertension Pipeline market research report of 73 pages is available at http://www.reportsnreports.com/reports/538071-portal-hypertension-pipeline-review-h1-2016.html .
Explore more reports on Pharmaceuticals.
About Us:
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
Connect With Us on:
Facebook: https://www.facebook.com/ReportsnReports/
LinkedIn: https://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml
Contact: Ritesh Tiwari UNIT no 802, Tower no. 7, SEZ Magarpatta city, Hadapsar Pune - 411013 Maharashtra, India. + 1 888 391 5441 [email protected]
SOURCE ReportsnReports
